Precision Medicine for Rheumatoid Arthritis: The Right Drug for the Right Patient—Companion Diagnostics
Open Access
- 29 July 2021
- journal article
- review article
- Published by MDPI AG in Diagnostics
- Vol. 11 (8), 1362
- https://doi.org/10.3390/diagnostics11081362
Abstract
Despite the growing number of biologic and JAK inhibitor therapeutic agents available to treat various systemic autoimmune illnesses, the lack of a validated companion diagnostic (CDx) to accurately predict drug responsiveness for an individual results in many patients being treated for years with expensive, ineffective, or toxic drugs. This review will focus primarily on rheumatoid arthritis (RA) therapeutics where the need is greatest due to poor patient outcomes if the optimum drug is delayed. We will review current FDA-approved biologic and small molecule drugs and why RA patients switch these medications. We will discuss the sampling of various tissues for potential CDx and review early results from studies investigating drug responsiveness utilizing advanced technologies including; multiplex testing of cytokines and proteins, autoantibody profiling, genomic analysis, proteomics, miRNA analysis, and metabolomics. By using these new technologies for CDx the goal is to improve RA patient outcomes and achieve similar successes like those seen in oncology using precision medicine guided therapeutics.Funding Information
- Eli Lily and Company (Global Health Outcomes Projct agreement 05.24.2016 to establish a RA registry at National Jewish Health)
This publication has 62 references indexed in Scilit:
- Where and how to inject the knee—A systematic reviewSeminars in Arthritis and Rheumatism, 2013
- Pretreatment synovial transcriptional profile is associated with early and late clinical response in rheumatoid arthritis patients treated with rituximabAnnals Of The Rheumatic Diseases, 2012
- Induction of osteoclastogenesis and bone loss by human autoantibodies against citrullinated vimentinJCI Insight, 2012
- Proteomic profiling following immunoaffinity capture of high‐density lipoprotein: Association of acute‐phase proteins and complement factors with proinflammatory high‐density lipoprotein in rheumatoid arthritisArthritis & Rheumatism, 2012
- The microbiome and rheumatoid arthritisNature Reviews Rheumatology, 2011
- Treatment of rheumatoid arthritis with tumour necrosis factor inhibitorsBritish Journal of Pharmacology, 2011
- Immune complexes containing citrullinated fibrinogen costimulate macrophages via Toll‐like receptor 4 and Fcγ receptorArthritis & Rheumatism, 2010
- Structure and pathogenicity of antibodies specific for citrullinated collagen type II in experimental arthritisThe Journal of Experimental Medicine, 2009
- Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2008
- Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker resultsAnnals Of The Rheumatic Diseases, 2007